Insight on Pharmaceuticals and Healthcare in North America

The following industries match your search criteria:

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

Results are sorted by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Market and Product Forecasts: Neuropathic Pain - Targeting underserved indications drives market growth

This report assesses the current and future neuropathic market accounting for the latest market events. The analysis is designed to understand the future dynamics of the neuropathic pain drug market.

Published By Datamonitor
14 Sep 2011 $6400
Buy
Report
Report

Market and Product Forecasts: Disease Modification in Rheumatoid Arthritis – Novel therapies plus reformulations poised to enter the market

Focusing on disease-modifying drugs, Datamonitor uses a patient-based approach to size the seven major rheumatoid arthritis markets from 2010 to 2020. Robust epidemiology forecasts, survey data and opinion leader discussions validate key assumptions.

Published By Datamonitor
08 Sep 2011 $6400
Buy
Report
Report

Product Profiles: Prostate Cancer – Recent approvals create competitive environment for new market entrants

Analysis of current market dynamics for the treatment of prostate cancer. The report assesses comparator therapies for prostate cancer, identifies key strategies for drug development, and analyzes commercial and clinical potential of pipeline drugs.

Published By Datamonitor
02 Sep 2011 $6400
Buy
Report
Report

Generics: Regulatory Update

Datamonitor’s report Generics: Regulatory Update provides an update of changes to generic regulations that occurred in the first half of 2011.

Published By Datamonitor
30 Aug 2011 $1520
Buy
Report
Report

Market and Product Forecasts: Systemic Lupus Erythematosus – Benlysta approval kicks off new era in lupus treatment

Benlysta’s US and EU approvals will change the lupus market considerably. With additional products moving through the pipeline, Datamonitor expects to see a significant shift from off- to on-label treatment over the next 10 years.

Published By Datamonitor
22 Aug 2011 $6400
Buy
Report
Report

Prescribing Influences: Multiple Sclerosis - Therapies that reverse neuronal damage are most sought after

This report analyzes the unmet needs of multiple sclerosis treatment and the attributes of drugs that influence prescribing decisions. The analysis aims to understand the opportunities in the market and support the positioning of marketed brands.

Published By Datamonitor
09 Aug 2011 $2800
Buy
Report
Report

Key Companies: Depression - Leading players must adapt to remain competitive

This report identifies the leading players that are active in the depression pharmaceutical market, evaluating trends in corporate strategy and discussing the impact of key recent licensing deals.

Published By Datamonitor
02 Aug 2011 $2800
Buy
Report
Report

Product Profiles: Obesity - Pipeline stalls as regulatory requirements escalate

Datamonitor module assesses the current state of the obesity pipeline and trends that will shape its future. Focused on the US, Japan, France, Germany, Italy, Spain, and the UK

Published By Datamonitor
19 Jul 2011 $6400
Buy
Report
Report

Product Profiles: Allergic Rhinitis - Heavily genericized market sees areas of innovation

Allergic rhinitis is an established, yet dynamic market. The April 2011 FDA filing of Dymista (azelastine/fluticasone; Meda/Cipla) could bring a new class to the market, while efforts to retain brand share have been seen in monotherapy classes.

Published By Datamonitor
23 Jun 2011 $6400
Buy
Report
Report

Prescribing Influences: Alzheimer's Disease - Alleviating symptoms remains the goal for prescribers

This report analyzes the unmet needs of Alzheimer’s disease treatment and the attributes of drugs that influence prescribing decisions. The analysis aims to understand the opportunities in the market and support the positioning of marketed brands.

Published By Datamonitor
13 Jun 2011 $2800
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

No help is available.